Clinical trial
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
NCT00003821 · Genzyme, a Sanofi Company, Industry · Withdrawn
Key facts
| NCT number | NCT00003821 |
|---|---|
| Title | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer |
| Official title | Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | aminopterin |
| Enrollment | 0 |
| Start date | Jan 1, 1998 |
| First posted | Aug 4, 2004 |
| Last update posted | Sep 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: